3/27
02:15 pm
eols
Aviva Aesthetics Partners with Nationally Recognized Injector Jordan White and Urban Medical, Expanding into Arizona and Virginia
Low
Report
Aviva Aesthetics Partners with Nationally Recognized Injector Jordan White and Urban Medical, Expanding into Arizona and Virginia
3/20
04:50 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/20
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/15
07:59 pm
eols
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference [Yahoo! Finance]
Low
Report
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference [Yahoo! Finance]
3/15
01:05 am
eols
Low
Report
3/12
07:29 pm
eols
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance [Yahoo! Finance]
Low
Report
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance [Yahoo! Finance]
3/9
12:47 pm
eols
Jeuveau (Evolus) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
Low
Report
Jeuveau (Evolus) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
3/5
04:22 pm
eols
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
Medium
Report
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
3/4
04:56 pm
eols
Evolus, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Evolus, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/4
08:00 am
eols
Evolus (EOLS) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.
High
Report
Evolus (EOLS) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.
3/4
02:48 am
eols
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/4
02:47 am
eols
Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]
High
Report
Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]
3/4
12:15 am
eols
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges [Yahoo! Finance]
High
Report
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges [Yahoo! Finance]
3/3
07:17 pm
eols
Evolus Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Evolus Q4 Earnings Call Highlights [Yahoo! Finance]
3/3
06:25 pm
eols
Evolus (EOLS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
High
Report
Evolus (EOLS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/3
04:20 pm
eols
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 [Yahoo! Finance]
High
Report
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 [Yahoo! Finance]
3/3
04:05 pm
eols
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026
High
Report
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026
2/25
08:00 am
eols
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Medium
Report
Evolus to Participate in The Leerink Partners Global Healthcare Conference
2/17
08:40 am
eols
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 [Yahoo! Finance]
Low
Report
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 [Yahoo! Finance]
2/17
08:00 am
eols
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Low
Report
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
2/13
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/9
02:43 pm
eols
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating [Yahoo! Finance]
Low
Report
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating [Yahoo! Finance]
2/4
10:15 am
eols
Evolus (NASDAQ:EOLS) was given a new $15.00 price target on by analysts at Mizuho.
Low
Report
Evolus (NASDAQ:EOLS) was given a new $15.00 price target on by analysts at Mizuho.
2/4
08:01 am
eols
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance]
Low
Report
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance]
2/4
07:56 am
eols
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance Canada]
Low
Report
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance Canada]